Hyderabad: Bharat Biotech has refuted the claim made about the vaccine, which said that more antibodies are produced from the Kovishield vaccine than the vaccine. One study said that most people taking Covishield had a higher sero-positivity rate than those taking Covaccine supplements. Now Bharat Biotech has rejected this study.
Study is a predetermined hypothesis- Company
Bharat Biotech has said, “There are many flaws in the study. The study is neither based on statistics nor scientifically designed. This is a pre-conceived notion.” The company said, “It will publish Phase 3 trial data in July and then apply for COVAXIN’s full license.”
The company said that this year the vaccination is going on since mid-January and till now lakhs of doses have been administered, so soon we will have a reliable and huge data. Serum Institute of India, Oxford-AstraZeneca’s Covishield is manufacturing the vaccine. At the same time, the Hyderabad-based company Bharat Biotech is manufacturing the covaccine in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
what the study said?
Antibodies and their levels were tested in the blood samples of the participants in the study conducted on health workers who had taken doses of both vaccines. Study author and Consultant Endocrinologist (Diabetologist) at GD Hospital & Diabetic Institute, Kolkata Awadhesh Kumar Singh tweeted, “Both vaccines worked to strengthen immunity after both doses. However, the sero-positivity rate and antibody level were higher in CoviShield compared to Covaccine.” Most people taking Covishield had higher sero-positivity rates than those taking Covaccine supplements.
515 health workers involved in the study
In this study, 515 health workers from 22 cities in 13 states were included. Of these, 305 were men and 210 were women. The authors of the study said, “Of 515 health workers, 95 percent showed sero-positivity after taking both doses of both vaccines. Of these, 425 people had taken Covashield and 90 people had taken Covaccine doses and the sero positivity rate was 98.1 percent and 80 percent respectively.